The concern of generic rivalry has repeatedly loomed above copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the outlook of connected drug portfolios. While initial periods saw impressive returns, the exclusivity lapse has opened the door for discounted copies, possibly lowering earnings and presenting a real hazard for investor